Myriad Genetics has made good on its promise to appeal a federal district court's recent determination that seven of its BRCA1/2 gene patents are invalid.
An appeals court has ruled in favor of Qiagen in an antitrust suit brought by Third Wave over HPV tests.
Cerenis, Montreal Heart Institute, UVA, Ortho Clinical, Mirna, UCSF, Case Western, Diagnostic Hybrids, iBridge Network, Ben Franklin Tech Partners, and more…
The American Prospect writes that the pilot program to test the DNA of migrants could lead to more family separations.
An international commission is to develop a report on how researchers, clinicians, and regulators should evaluate the clinical applications of human germline genome editing.
The US Department of Agriculture presents a new blueprint for animal genomic research.
In Genome Research this week: repetitive element deletion linked to altered methylation and more in form of muscular dystrophy; human contamination in draft bacterial and archaeal genomes; and more.